Full Press Release Details
THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING
Calif., and VANCOUVER, British Columbia, May 19, 2021 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell"
or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast
cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the "Shareholders")
for the years ended July 31, 2019 and July 31, 2020 held on May 18, 2021 (the "Meeting"). A total of 1,685,180 common
shares of the Company (the "Common Shares") were voted, representing 22.36% of the Company's issued and outstanding
Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions that consisted of the following:
| 1. | The number of directors set at six; | |
| 2. | Election of Dr. William V. Williams, Mr. Jamieson Bondarenko, Dr. Charles Wiseman, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin Schmieg as directors of the Company; | |
| 3. | Appointment of MNP LLP as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration; | |
| 4. | Renewal of the Company's stock option plan; | |
| 5. | Ratification of the number of directors set at six for the prior year ended July 31, 2019; | |
| 6. | Ratification of the election of Dr. William V. Williams, Mr. Jamieson Bondarenko, Mr. Richard Berman, Mr. Vaughn C. Embro-Pantalony, Dr. Rebecca Taub, and Dr. Charles Wiseman as directors of the Company for the prior year ended July 31, 2019; | |
| 7. | Ratification of the appointment of MNP LLP as the auditors of the Company for the prior year ended July 31, 2019 and ratifying the directors authorization to fix their remuneration; | |
| 8. | Ratification of the Company's stock option plan for the prior year ended July 31, 2019; and | |
| 9. | Ratification of holding the Company's annual general and special meeting for the year ended July 31, 2019 on May 18, 2021. |
received Shareholder approval, the Company's stock option plan remains subject to approval from the TSX Venture Exchange. The formal
report on voting results with respect to all maters voted upon during the Meeting will be filed on the Company's SEDAR profile at www.sedar.com.
is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
additional information on BriaCell, please visit: https://briacell.com/.
Note Regarding Forward-Looking Information
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section
titled "Risk Factors" in the Company's SEC filings. Forward-looking statements contained in this announcement are made
as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
further information, please contact: